HALO News and Press, Halozyme Therapeutics Inc. From 11/12/19

Image source: The Motley Fool. Halozyme Therapeutics Inc   (NASDAQ: HALO) Q3 2019 Earnings Call Nov 12, 2019 , 4:30 p.m. ET Operator Continue reading

Halozyme Therapeutics, Inc. (HALO) Q3 2019 Earnings Conference Call November 12, 2019 4:30 PM ET Company Participants Albert Kildani - Vice President of Investor Relations and Corporate Communications Helen Torley - President and Chief Executive Officer Laurie Stelzer - Chief Fin...

Gainers: CDLX   +20.8% . TWOU   +14.6% . DDOG   +14.2% . VRAY   +9.3% . NBRV   +8.4% . More news on: Cardlytics, Inc., 2U, Inc., Datadog, Inc., Stocks on the move, Read more ...

MORRISVILLE, N.C., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Syneos Health ® (Nasdaq:SYNH), a leading biopharmaceutical solutions organization combining a Contract Research Organization (CRO) and a Contract Commercial Organization (CCO), today announced the appointment of Bernadette Connaught...

Halozyme (NASDAQ: HALO ) Q3 results : More news on: Halozyme Therapeutics, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...

SAN DIEGO , Nov. 12, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (the "Company"), a biotechnology company focused on novel biological and drug delivery approaches, today announced that it intends to offer, subject to market conditions and other factors, $400...

Halozyme Therapeutics (NASDAQ: HALO ): Q3 GAAP EPS of -$0.17 misses by $0.05 . Revenue of $46.2M (+80.8% Y/Y) misses by $8.76M . Press Release More news on: Halozyme Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news,

SAN DIEGO , Nov. 12, 2019 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the third quarter ended September 30, 2019 and provided an update on its recent corporate activities and outlook. "We have transitioned our strategy to foc...

Halozyme Therapeutics (NASDAQ: HALO ) is scheduled to announce Q3 earnings results on Tuesday, November 12th, after market close. The consensus EPS Estimate is -$0.12 (+36.8% Y/Y) and the consensus Revenue Estimate is $54.96M (+114.7% Y/Y). Over the last 2 years, halo has beaten EPS e...

Halozyme Therapeutics ( HALO ) announced that its product PEGPH20 failed to achieve statistical significance in a phase 3 study treating patients with metastatic pancreatic cancer. This was a major setback for the company and its shareholders. However, this move prompted it to move quickly...